NCT00618176 - Three Generic Nevirapine-Based Antiretroviral Treatments in Chinese Patients:Multicentric Observation Cohort | Biotech Hunter

Enrollment

198

Participants

Timeline

Start Date

January 31, 2005

Primary Completion Date

September 30, 2006

Conditions

HIV Infections

Interventions

DRUG

Zidovudine (AZT)+ Didanosine (ddI)+ Nevirapine (NVP)

Zidovudine (AZT) 300mg bid Didanosine (ddI) 200mg bid (W\>60Kg)125mg bid (W\<60Kg) Nevirapine (NVP) 200mg bid

DRUG

Stavudine (d4T), Lamivudine (3TC), Nevirapine (NVP)

Stavudine (d4T) 30mg bid (W\>60Kg)20mg bid (W\<60Kg) Lamivudine (3TC)300mg qd Nevirapine (NVP)200mg bid

DRUG

Zidovudine (AZT), Lamivudine (3TC), Nevirapine (NVP)

Zidovudine (AZT) 300mg bid Lamivudine (3TC) 300mg qd Nevirapine (NVP) 200mg bid

Trial Locations (1)

Peking Union Medical College Hospital, Beijing

All Listed Sponsors

collaborator

Ministry of Science and Technology of the People´s Republic of China

OTHER_GOV

lead

Peking Union Medical College

OTHER